Acadian Asset Management
PSTX

Acadian Asset Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Acadian Asset Management’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-933,102
Closed -$8.96M – 1859
2024
Q4 		$8.96M Buy
933,102
+102,061
+12% +$533K 0.03% 386
2024
Q3 		$2.38M Buy
831,041
+431,202
+108% +$1.33M 0.01% 696
2024
Q2 		$1.17M Buy
399,839
+34,321
+9% +$93.9K ﹤0.01% 946
2024
Q1 		$1.17M Sell
365,518
-136,201
-27% -$454K ﹤0.01% 803
2023
Q4 		$1.69M Sell
501,719
-350,120
-41% -$902K 0.01% 716
2023
Q3 		$2.02M Sell
851,839
-259,533
-23% -$544K 0.01% 690
2023
Q2 		$1.95M Buy
1,111,372
+99,989
+10% +$255K 0.01% 698
2023
Q1 		$3.12M Buy
1,011,383
+811,819
+407% +$4.87M 0.01% 591
2022
Q4 		$1.06M Buy
+199,564
New +$912K 0.01% 829
2022
Q3 		– Sell
-12,099
Closed -$31K – 1890
2022
Q2 		$31K Buy
+12,099
New +$33.6K ﹤0.01% 1569

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Acadian Asset Management's PSTX Position: Q1 2025 in Review

Acadian Asset Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 933,102 shares — an estimated $8.96M sold.

Acadian Asset Management first reported a position in PSTX in Q2 2022 and held it in 10 quarters. The position peaked at $8.96M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Acadian Asset Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Acadian Asset Management sold 933,102 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $8.96M.
  • Acadian Asset Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q2 2022 and held it in 10 quarters.
  • Acadian Asset Management's Poseida Therapeutics, Inc. Common Stock position peaked at $8.96M in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Acadian Asset Management's 13F filing for Q1 2025, filed 21 May 2025.